KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edwards Lifesciences (EW) Other financing activities (2016 - 2025)

Historic Other financing activities for Edwards Lifesciences (EW) over the last 17 years, with Q3 2025 value amounting to -$2.4 million.

  • Edwards Lifesciences' Other financing activities rose 7647.06% to -$2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$600000.0, marking a year-over-year increase of 5000.0%. This contributed to the annual value of -$3.1 million for FY2024, which is 13846.15% down from last year.
  • Edwards Lifesciences' Other financing activities amounted to -$2.4 million in Q3 2025, which was up 7647.06% from $1.0 million recorded in Q2 2025.
  • Edwards Lifesciences' 5-year Other financing activities high stood at $7.2 million for Q2 2024, and its period low was -$10.2 million during Q3 2024.
  • Its 5-year average for Other financing activities is -$511111.1, with a median of $0.0 in 2021.
  • Its Other financing activities has fluctuated over the past 5 years, first crashed by 190000.0% in 2022, then surged by 190000.0% in 2023.
  • Over the past 5 years, Edwards Lifesciences' Other financing activities (Quarter) stood at $700000.0 in 2021, then plummeted by 85.71% to $100000.0 in 2022, then surged by 1900.0% to $2.0 million in 2023, then crashed by 95.0% to $100000.0 in 2024, then tumbled by 2500.0% to -$2.4 million in 2025.
  • Its Other financing activities stands at -$2.4 million for Q3 2025, versus $1.0 million for Q2 2025 and $700000.0 for Q1 2025.